|4Jan 10, 6:18 PM ET

Patterson Matthew R 4

4 · Audentes Therapeutics, Inc. · Filed Jan 10, 2020

Insider Transaction Report

Form 4
Period: 2019-12-26
Patterson Matthew R
DirectorPresident & CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2020-01-08$9.50/sh+11,824$112,328249,792 total
  • Exercise/Conversion

    Common Stock

    2020-01-08$15.26/sh+11,666$178,023261,458 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-01-0874,2970 total
    Exercise: $2.19Exp: 2025-02-04Common Stock (74,297 underlying)
  • Gift

    Common Stock

    2019-12-2612,50098,920 total
  • Exercise/Conversion

    Common Stock

    2020-01-08$0.78/sh+64,751$50,506163,671 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-01-0864,7510 total
    Exercise: $0.78Exp: 2023-09-25Common Stock (64,751 underlying)
  • Exercise/Conversion

    Common Stock

    2020-01-08$2.19/sh+74,297$162,710237,968 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-01-0811,824143,569 total
    Exercise: $9.50Exp: 2025-12-18Common Stock (11,824 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-01-0811,666188,334 total
    Exercise: $15.26Exp: 2027-01-25Common Stock (11,666 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    171,814
Footnotes (5)
  • [F1]The reporting person is the trustee of the Matthew R. Patterson Revocable Trust.
  • [F2]The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017.
  • [F3]The option vested as to 25% of the total shares on February 4, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 4, 2019.
  • [F4]The option vested as to 6.25% of the total shares quarterly, beginning March 18, 2016, with 100% of the total shares vested and exercisable on December 18, 2019.
  • [F5]The option vests as to 2.0833% of the total shares monthly, beginning February 25, 2017, with 100% of the total shares vested and exercisable on January 25, 2021, subject to the reporting person's provision of service to the issuer on each vesting date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION